Related Experiment Video
Updated: Aug 17, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Percutaneous left atrial appendage closure using the LAmbre device in patients with atrial fibrillation and left
Lu-Shen Jin1, Jin-Yan Ke1, Yuan-Nan Lin1
1Department of Cardiology, Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Insights
Left atrial appendage closure (LAAC) using the LAmbre device is a safe and effective treatment for preventing stroke in patients with persistent left atrial appendage thrombus (LAAT). This study demonstrates successful outcomes in selected patients, highlighting the device
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Persistent left atrial appendage thrombus (LAAT) poses a risk for thromboembolic stroke.
- Left atrial appendage closure (LAAC) is an alternative stroke prevention strategy.
- Limited data exists on LAAC with the LAmbre device for LAAT patients.
Purpose of the Study:
- To evaluate the efficacy and safety of modified LAAC with the LAmbre device in patients with LAAT.
- To share procedural experience with the LAmbre device in this patient population.
Main Methods:
- A modified LAAC procedure using the LAmbre device was performed on 7 patients with persistent LAAT.
- Transesophageal echocardiography was used for postoperative assessment of device-related thrombosis and peridevice leak.
- Clinical events were monitored during perioperative and follow-up periods.
Main Results:
- Successful LAAC with the LAmbre device was achieved in all patients without perioperative complications.
- During a median follow-up of 383 days, one patient (16.7%) developed device-related thrombosis.
- No significant peridevice leak, thromboembolic events, or bleeding events were observed.
Conclusions:
- Modified LAAC with the LAmbre device is effective and safe for selected patients with LAAT.
- Experienced operators can achieve positive outcomes in this challenging patient group.
Background:
Left atrial appendage closure (LAAC) is considered a valid alternative for the prevention of thromboembolic stroke in patients with persistent left atrial appendage thrombus (LAAT) despite adequate anticoagulation. However, the data on LAAC using the LAmbre device for patients with LAAT is limited. This study was performed to explore efficacy and safety as well as to share the experience of the modified LAAC procedure with the LAmbre device.
Materials And Methods:
A total of 7 patients with persistent LAAT despite adequate anticoagulation underwent modified LAAC with the LAmbre device between November 2019 and April 2022. Transesophageal echocardiography was performed 3 months postoperatively to detect device-related thrombosis and peridevice leak. The patients' clinical events were evaluated during the perioperative and follow-up periods.
Results:
The median age, CHA2DS2-VASc score, and HAS-BLED score of all patients were 71 [53-73], 3 [2-4], and 2 [2-3], respectively. In the procedure, a cerebral protection system was used in two patients. LAAC with the LAmbre device was successfully performed in all patients without perioperative events. During the median follow-up of 383 [325-865] days, postoperative transesophageal echocardiography was performed in six (85.7%) patients. Device-related thrombosis was detected in one (16.7%) patient, and no significant peridevice leak was observed. No thromboembolic event or bleeding event occurred in any patients.
Conclusion:
LAAC with the LAmbre device is effective and safe when performed by experienced operators in highly selected patients with LAAT after adequate anticoagulation.
